Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD).
美国马萨诸塞州剑桥市，2024年6月12日(GLOBE NEWSWIRE)——fulcrum therapeutics董事会(Nasdaq: FULC)宣布，该公司将在2024年6月13日至14日举行的第31届FSHD学会国际研究大会上做出即将到来的演讲，这包括一篇摘要，概述了losmapimod在面部、肩胛骨和上臂肌肉萎缩症(FSHD)3期REACH试验中，患者基线特征的情况。作为一家临床阶段生物制药公司，fulcrum therapeutics专注于开发小分子药物，改善患有基因定义罕见疾病的患者的生活。(纳斯达克：FULC)21世纪医疗改革法案本次演讲的主题如下:
The presentations to be made are as follows:
所做的演讲如下所示：
Title: Characteristics of the Enrolled Population in the Phase 3 REACH Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
Poster Number: P7.01
Format: Poster
First Author: Nicol Voermans, MD, PhD, Radboud University Medical Center
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
题目：面部、肩胛骨和上臂肌肉萎缩症(FSHD)3期REACH试验中受试者群体的特征
海报编号：P7.01
格式：海报
第一作者：Nicol Voermans, MD, PhD，Radboud大学医学中心
演示日期和时间：2024年6月13日星期四，MDT时间下午5:30至8:30之间
Title: Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms
Presentation Number: S6.06
Format: Oral presentation
Presenter: Joost Kools, MD, Radboud University Medical Center
Presentation Date and Time: Friday, June 14, 2024 at 3:50 PM MDT
题目：通过可达工作区域评估面部、肩胛骨和上臂肌肉萎缩症(FSHD)疾病进展和Losmapimod疗效
演讲编号：S6.06
格式：口头报告
演讲者：Joost Kools, MD，Radboud大学医学中心
演讲日期和时间：2024年6月14日星期五下午3:50 MDT
Title: Safety and Tolerability of Losmapimod for the Treatment of FSHD
Poster Number: P6.05
Format: Poster
First Author: Mihaela Levitchi Benea, MD, Executive Director of Medical Affairs at Fulcrum Therapeutics
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
题目：Losmapimod治疗FSHD的安全性和耐受性
海报编号：P6.05
格式：海报
第一作者：Mihaela Levitchi Benea, MD，fulcrum therapeutics医学事务执行主任
演示日期和时间：2024年6月13日星期四，MDT时间下午5:30至8:30之间
Title: Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in
Facioscapulohumeral Muscular Dystrophy
Poster Number: P7.06
Format: Poster
First Author: Lena Hubig, Acaster Lloyd Consulting
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
题目：使用手腕重量对可达工作区域总分数的可靠性和有效性进行评估
肌肉萎缩性侧腹肌肌 dystrophy
海报编号：P7.06
格式：海报
第一作者：Lena Hubig，阿卡斯特洛伊德咨询
演示日期和时间：2024年6月13日星期四，MDT时间下午5:30至8:30之间
The presentation and posters will be available on the publications page of Fulcrum's website at
演示和海报可在Fulcrum网站的出版物页面上进行查看
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Fulcrum Therapeutics是一家临床阶段的生物制药公司，专注于开发小分子化合物，改善遗传定义罕见病领域的高度医疗需求患者的生活质量。Fulcrum在临床开发中的两个主要项目是losmapimod，一种用于治疗面肌肩带肌肌肉萎缩症（FSHD）的小分子化合物，以及pociredir，一种设计用于增加胎儿血红蛋白表达并用于治疗镰状细胞病（SCD）和其他血红蛋白病的小分子化合物。Fulcrum使用专有技术识别药物靶点，以调节基因表达来治疗已知的基因错配根本原因。有关更多信息，请访问并在Twitter/X上关注我们（@FulcrumTx）和LinkedIn。
Fulcrum Therapeutics是一家临床阶段的生物制药公司，致力于开发小分子药物，改善罕见遗传性疾病患者在高度未满足医疗需求领域的生活质量。Fulcrum的两个领先临床开发项目是losmapimod，一种小分子药物，用于治疗肌肉萎缩性侧腹肌肌萎缩症（FSHD），以及pociredir，一种小分子药物，旨在增加胎儿血红蛋白的表达，并用于治疗镰状细胞贫血症（SCD）和其他血红蛋白病。Fulcrum使用专有技术识别可调节基因表达以治疗已知基因错配根本原因的药物靶点。欲了解更多信息，请访问网站并关注我们的Twitter / X（@ FulcrumTx）和LinkedIn。
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
联系方式：
Chris Calabrese
LifeSci Advisors，LLC
ccalabrese@lifesciadvisors.com
917-680-5608